

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addease COMMISSIONER FOR PATENTS PO Box 1430 Alexandra, Virginia 22313-1450 www.webjo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/531,375	04/15/2005	Volker Reiffenrath	MERCK-2995	6208	
23599 7550 MILLEN, WHITE, ZELANO & BRANIGAN, P.C. 2200 CLARENDON BLVD. SUITE: 1400 ARLINGTON, VA 22201			EXAM	EXAMINER	
			VISCONTI, O	VISCONTI, GERALDINA	
			ART UNIT	PAPER NUMBER	
			1795		
			MAIL DATE	DELIVERY MODE	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/531,375 REIFFENRATH ET AL Office Action Summary Examiner Art Unit Geraldina Visconti 1795 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 15 April 2005. 2a) ☐ This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-7 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) 1-7 is/are rejected. 7) Claim(s) _____ is/are objected to. 8) Claim(s) _____ are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) \(\begin{align*}{l} \lambda \text{Notice of References Cited (PTO-892)} \)
2) \(\begin{align*}{l} \lambda \text{Notice of Draitsperson's Patient Drawing Review (PTO-948)} \)
3) \(\begin{align*}{l} \lambda \text{Notice of Information Disclosure Statement(s) (PTO/SSIGE)} \)
2) \(\begin{align*}{l} \lambda \text{Notice of Information Patient At *p* lication} \)
2) \(\begin{align*}{l} \lambda \text{Notice of Information Patient At *p* lication} \)
2) \(\begin{align*}{l} \lambda \text{Notice of Information Patient At *p* lication} \)
3) \(\begin{align*}{l} \lambda \text{Notice of Information Patient At *p* lication} \)
3) \(\begin{align*}{l} \lambda \text{Notice of Information Patient At *p* lication} \)
3) \(\begin{align*}{l} \lambda \text{Notice of Information Patient At *p* lication} \)
3) \(\begin{align*}{l} \lambda \text{Notice of Information Patient At *p* lication} \)
4) \(\begin{align*}{l} \lambda \text{Notice of Information Patient At *p* lication} \)
4) \(\begin{align*}{l} \lambda \text{Notice of Information Patient At *p* lication} \)
4) \(\begin{align*}{l} \lambda \text{Notice of Information Patient At *p* lication} \)
4) \(\begin{align*}{l} \lambda \text{Notice of Information Patient At *p* lication} \)
4) \(\begin{align*}{l} \lambda \text{Notice of Information Patient At *p* lication} \)
4) \(\begin{align*}{l} \lambda \text{Notice of Information Patient At *p* lication} \)
4) \(\begin{align*}{l} \lambda \text{Notice of Information Patient At *p* lication} \)
4) \(\begin{align*}{l} \lambda \text{Notice of Information Patient At *p* lication} \)
4) \(\begin{align*}{l} \lambda \text{Notice of Information Patient At *p* lication} \)
4) \(\begin{align*}{l} \lambda \text{Notice of Information Patient At *p* lication} \)
4) \(\begin{align*}{l} \lambda \text{Notice of Information Patient At *p* lication} \)
4) \(\begin{align*}{l} \lambda \text{Notice of Information Patient At *p* lication} \)
4) \(\begin{align*}{l} \lambda \text{Notice of Information Patient At *p* licat

Application/Control Number: 10/531,375

Art Unit: 1795

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-7 are rejected under 35 U.S.C. 102(b) as being anticipated by either Coates et al. (U.S. Patent No. 5,958,290) or Reiffenrath et al. (6,056,893).

Each of Coates et al. and Reiffenrath et al. discloses chiral dopants and their use thereof in the liquid-crystal mixtures contained in liquid-crystal displays, said dopants inclusive of the instant claims and having a laterally alkylated phenyl unit.

Prior Art

The following prior art made of record and not relied upon is considered pertinent to applicants' disclosure:

- U.S. Patent No. 6,146720 to Pausch et al.
- U.S. Patent No. 5,993,691 to Pausch et al.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Geraldina Visconti whose telephone number is (571) 272-1334. The examiner can normally be reached 8:00am to 4:30pm.

Application/Control Number: 10/531,375 Page 3

Art Unit: 1795

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cynthia Kelly can be reached on (571) 272-1526. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Geraldina Visconti/ Primary Examiner, Art Unit 1795